Vonoprazan Fumarate

CAS No. 881681-01-2

Vonoprazan Fumarate( TAK-438 | TAK 438 | TAK438 | Vonoprazan Fumurate )

Catalog No. M27383 CAS No. 881681-01-2

Vonoprazan Fumurate, a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumurate inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 37 In Stock
200MG 59 In Stock
500MG 127 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Vonoprazan Fumarate
  • Note
    Research use only, not for human use.
  • Brief Description
    Vonoprazan Fumurate, a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumurate inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.
  • Description
    Vonoprazan Fumurate, a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumurate inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5.(In Vitro):The inhibitory activity of Vonoprazan Fumurate was unaffected by ambient pH. The inhibition by Vonoprazan Fumurate was reversible and achieved in a K(+)-competitive manner, quite different from that by lansoprazole. Vonoprazan Fumurate exhibits porcine gastric H+ ,K+-ATPase activity in a concentration-dependent manner.(In Vivo):Vonoprazan Fumurate, at a dose of 4 mg/kg (as the free base) orally, completely inhibited basal and 2-deoxy-d-glucose-stimulated gastric acid secretion in rats, and its effect on both was stronger than that of lansoprazole. Vonoprazan Fumurate increased the pH of gastric perfusate to a higher value than did lansoprazole or SCH28080, and the effect of Vonoprazan Fumurate was sustained longer than that of lansoprazole or SCH28080.
  • In Vitro
    Vonoprazan (0.1 nM-10 μM; 30 minutes) exhibits porcine gastric H+ ,K+-ATPase activity in a concentration-dependent manner.Vonoprazan does not inhibit Na+,K+-ATPase activity, even at concentrations 500 times higher than their IC50 values against gastric H+,K+-ATPase activity.
  • In Vivo
    Vonoprazan (1-4 mg/kg; p.o.) completely inhibits basal and 2-deoxy-D-glucose (2DG, 200 mg/kg s.c.)-stimulated gastric acid secretion at the 4 mg/kg dose in rats. Animal Model:Male 7- or 8-week-old Sprague-Dawley rat Dosage:0.5, 1, 2, and 4 mg/kg.Administration:Oral administration Result:Inhibited basal gastric acid secretion in a dose-dependent manner.
  • Synonyms
    TAK-438 | TAK 438 | TAK438 | Vonoprazan Fumurate
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Proton Pump
  • Recptor
    Antiviral
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    881681-01-2
  • Formula Weight
    461.46
  • Molecular Formula
    C21H20FN3O6S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 50 mg/mL (108.35 mM)
  • SMILES
    OC(=O)\C=C\C(O)=O.CNCc1cc(-c2ccccc2F)n(c1)S(=O)(=O)c1cccnc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Yu W, Goddard C, Clearfield E, Mills C, Xiao T, Guo H, Morrey JD, Motter NE, Zhao K, Block TM, Cuconati A, Xu X. Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. J Med Chem. 2011 Aug 25;54(16):5660-70. doi: 10.1021/jm200696v. Epub 2011 Aug 2. PubMed PMID: 21786803; PubMed Central PMCID: PMC3158247.
molnova catalog
related products
  • Ilaprazole sodium

    Ilaprazole is a substituted benzimidazole prodrug with selective and irreversible proton pump inhibitor activity.

  • Pantoprazole

    A proton pump inhibitor that inhibits gastric acid secretion; works on gastric parietal cells to irreversibly inhibit (H+/K+)-ATPase function and suppress the production of gastric acid.

  • Rabeprazole Related ...

    Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.